Last updated: February 27, 2026
What is PONVORY?
PONVORY (ponesimod) is a selective S1P receptor modulator approved for relapse prevention in relapsing multiple sclerosis (RMS). It offers an oral, once-daily dosing alternative to existing therapies, with a targeted mechanism that reduces lymphocyte migration. PONVORY is marketed by Bayer and attained approval in 2020 [1].
What are the key excipient components in PONVORY formulations?
The commercial formulation of PONVORY primarily contains the active ingredient ponesimod, alongside excipients that ensure stability, bioavailability, and patient safety. The excipients include:
- Microcrystalline cellulose: Diluent and binder
- Magnesium stearate: Lubricant
- Lactose monohydrate: Fillers
- Hypromellose (HPMC): Coating agent
- Titanium dioxide: Opacity and color
- Iron oxide black: Colorant (for identification in different strengths)
These excipients comply with pharmacopeial standards (e.g., USP, EP) and are common in oral solid dosage forms [2].
How do excipients influence the drug’s formulation?
Excipients impact:
- Stability: Protect against moisture and light, e.g., titanium dioxide provides opacity, shielding ponesimod from photodegradation.
- Bioavailability: Disintegration and dissolution depend on fillers like microcrystalline cellulose or lactose.
- Manufacturing: Lubricants such as magnesium stearate minimize tablet sticking during compression.
- Patient Experience: Flavoring agents or colorants can improve compliance, especially for daily oral medications.
The choice of excipients aligns with PONVORY’s chronic dosing requirements, ensuring consistent performance and shelf stability [3].
What are the commercial opportunities surrounding excipient innovation for PONVORY?
While current excipient uses follow standard formulations, several avenues exist for innovation and differentiation:
1. Enhanced Stability and Shelf Life
Developing excipient systems with improved moisture resistance extends shelf life and reduces storage constraints, especially in regions with variable climates. Incorporation of moisture-scavenging agents or alternative coatings could achieve this.
2. Flexible Formulations (e.g., Orally Disintegrating Tablets)
Transitioning to formulations like orally disintegrating tablets (ODTs) can improve patient compliance, particularly for those with swallowing difficulties. This requires excipient systems with rapid disintegration properties, such as superdisintegrants (croscarmellose sodium, sodium starch glycolate).
3. Reduced Use of Lactose and Allergens
Lactose intolerance prevalence suggests potential market expansion through excipient substitutions, replacing lactose with alternative fillers (e.g., microcrystalline cellulose or mannitol).
4. Novel Coating Technologies
Advanced coating polymers with tailored dissolution profiles could optimize drug release, reduce gastrointestinal irritation, and improve pharmacokinetics.
5. Proprietary Excipients in Branding and Differentiation
Developing or licensing proprietary excipient systems that enhance stability, taste, or bioavailability can provide market differentiation. For instance, using coated or matrix-forming excipients for controlled-release formulations.
Regulatory Landscape
Any excipient innovation must navigate regulatory approval processes, including demonstrating GRAS status and ensuring compatibility with ponesimod’s chemical profile [4].
What are the strategic considerations for pharmaceutical companies?
- Cost efficiency: Balancing excipient quality with manufacturing costs.
- Patient-centric design: Focus on formulations that improve compliance.
- Global supply chain: Ensuring excipient availability across markets.
- Regulatory compliance: Securing approvals for novel excipients or formulations.
Commercialization of innovative excipients can open licensing, co-development, or co-commercialization opportunities. It also can reduce competition with standard formulations in established markets.
What regulatory pathways influence excipient development for PONVORY?
- US: 21 CFR Part 210/211; additional guidance on excipient use and Novel Excipient Notification.
- EU: EMA guidelines on excipient qualification; requirements for generic and biosimilar approvals.
- Japan: PMDA standards for pharmaceutical excipients, emphasizing purity and stability.
Use of novel excipients or significant formulation changes requires extensive stability data, in vitro dissolution studies, and clinical assessments where applicable.
Key Takeaways
- PONVORY formulations rely on standard excipients ensuring stability, bioavailability, and manufacturability.
- Excipient innovation offers opportunities for enhanced stability, patient-specific formulations, and differentiation.
- Regulatory pathways dictate the scope of excipient modifications, emphasizing safety and compatibility.
- Strategic focus on excipient supply chain, compliance, and patient-centric design can expand market share.
FAQs
Q1: Can excipient innovation extend PONVORY’s patent life?
A: Yes, modified formulations with new excipients can qualify for additional patent protection through incremental innovation.
Q2: Are there opportunities for natural excipients in PONVORY formulations?
A: Natural excipients appeal to certain markets but require thorough testing for stability and bioavailability.
Q3: How significant is excipient choice for patient compliance?
A: Minor excipient properties can influence taste, swallowability, and side effects, impacting adherence.
Q4: What are the challenges of switching to alternative excipients?
A: Compatibility issues and regulatory compliance require extensive testing.
Q5: How does excipient selection impact global supply chains?
A: Standardized excipients facilitate scalability, but proprietary or rare excipients may introduce supply risks.
References
[1] Bayer. (2020). PONVORY (ponesimod) summary of product characteristics.
[2] USP. (2021). Pharmaceutical Excipients: USP-NF.
[3] EU Guidance. (2018). Guidelines on pharmaceutical development.
[4] FDA. (2022). Guidance for Industry: Chemistry, Manufacturing, and Controls (CMC).
